Moleculin Biotech (MOL) Financial Statements
Moleculin Biotech Financial Overview
Moleculin Biotech's market cap is currently $7.40M. The company's EPS TTM is $-342.60; its P/E ratio is -0.02; Moleculin Biotech has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -90.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -25.10M | $ -26.64M | $ -29.63M | $ -30.64M | $ -22.97M |
| EBITDA | $ -33.47M | $ -21.64M | $ -29.64M | $ -28.89M | $ -15.73M |
| Net Income | $ -33.56M | $ -21.76M | $ -29.77M | $ -29.02M | $ -15.89M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 8.88M | $ 4.28M | $ 23.55M | $ 43.15M | $ 70.90M |
| Total Assets | $ 22.13M | $ 16.93M | $ 38.22M | $ 57.42M | $ 84.09M |
| Total Debt | $ 359.00K | $ 478.00K | $ 574.00K | $ 451.00K | $ 159.00K |
| Net Debt | $ -8.52M | $ -3.80M | $ -22.98M | $ -42.69M | $ -70.74M |
| Total Liabilities | $ 7.12M | $ 10.95M | $ 12.14M | $ 5.23M | $ 5.10M |
| Stockholders' Equity | $ 15.01M | $ 5.98M | $ 26.07M | $ 52.19M | $ 78.99M |
| Cash Flow | |||||
| Free Cash Flow | $ -22.73M | $ -23.88M | $ -24.23M | $ -27.71M | $ -18.97M |
| Operating Cash Flow | $ -22.73M | $ -23.86M | $ -24.10M | $ -27.64M | $ -18.95M |
| Investing Cash Flow | $ 0.00 | $ -13.00K | $ -124.00K | $ -67.00K | $ -19.00K |
| Financing Cash Flow | $ 27.28M | $ 4.63M | $ 4.65M | $ -23.00K | $ 74.72M |
Currency in USD